Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ramoplanin oral

Drug Profile

Ramoplanin oral

Alternative Names: A 16686; A 16686A; MDL 62198; NTI-851; Ramoplanin

Latest Information Update: 01 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Ology Bioservices
  • Class Antiacnes; Antibacterials; Depsipeptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Vancomycin-resistant enterococcal infections
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Clostridium difficile infections; Vancomycin-resistant enterococcal infections

Most Recent Events

  • 01 Feb 2018 Discontinued - Phase-II for Clostridium difficile infections in USA (PO) (Ology Bioservices communication, February 2018)
  • 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
  • 25 Jun 2015 Phase-II development in Clostridium difficile infections is ongoing in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top